Science

Piet Ost: Does SBRT for oligorecurrent prostate cancer improve OS as compared to SOC?

Piet Ost/X

Jan 19, 2025, 07:56

Piet Ost: Does SBRT for oligorecurrent prostate cancer improve OS as compared to SOC?

Piet Ost, Radiation Oncologist Iridium Network Antwerp, shared a post on X about a recent abstract by him and colleagues, presented at 2025 ASCO Genitourinary Cancers Symposium:

“Does SBRT for oligorecurrent prostate cancer improve overall survival as compared to SOC? WOLVERINE reporting on STOMP, ORIOLE, EXTEND and ARTO.

Presented by Chad Tang at GU25.”

“World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.”

Authors: Chad Tang, Alexander Sherry, Hyunsoo Hwang, David Palma, Piet Ost et al.

Piet Ost: Does SBRT for oligorecurrent prostate cancer improve OS as compared to SOC?

2025 ASCO Genitourinary Cancers Symposium Alexander Sherry cancer Chad Tang David Palma GU25 Hyunsoo Hwang OncoDaily Oncology Piet Ost prostate cancer WOLVERINE

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success